Division of General Internal Medicine, Department of Medicine, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Office of Population Research, Princeton University, Princeton, NJ, USA.
Lancet Glob Health. 2020 Jun;8(6):e829-e839. doi: 10.1016/S2214-109X(20)30121-2.
Disease Control Priorities, 3rd edition (DCP3), published two model health benefits packages (HBPs). This study estimates the overall costs and individual component costs of these packages in low-income countries (LICs) and lower-middle-income countries (lower-MICs).
This study reports on our Disease Control Priorities Cost Model (DCP-CM), developed as part of the DCP3 project to determine the overall costs of the 218 health sector interventions recommended in the model HBP termed essential universal health coverage (EUHC). Model inputs included data on intervention unit costs, demographic and epidemiological data to quantify the populations in need of specific interventions, baseline coverage indicators, and estimates of required health system costs to support direct service delivery. The DCP-CM was informed primarily by published estimates of economic costs of interventions measured from the health system perspective. We estimated counterfactual annual costs for the year 2015. We disaggregated costs according to intervention characteristics (delivery platform, delivery timing, and health system objective) and did one-way and probabilistic sensitivity analyses with determination of 95% credible intervals (Crls).
At 80% population coverage, the annual cost of EUHC would be US$79 (95% Crl 60-110) per capita (in 2016 US dollars) in LICs and US$130 (100-180) per capita in lower-MICs. As a share of 2015 gross national income (GNI), additional investments would require 8·0% (95% Crl 5·7-11·3) in LICs and 4·2% (2·9-5·9) in lower-MICs. A highest priority subpackage comprising 115 of the EUHC interventions would cost approximately half of these amounts (3·7% [2·6-5·3] of 2015 GNI in LICs and 2·0% [1·4-2·8] in lower-MICs). Mortality-reducing interventions would require around two-thirds of the overall package costs, with interventions to reduce mortality at age 5-69 years from non-communicable disease and injury comprising the highest share of total EUHC costs in both income groups (37·6% [37·2-37·9] in LICs and 43·0% [42·6-43·4] in lower-MICs). Interventions addressing chronic health conditions (requiring 45·5% [44·8-46·4] 2015 GNI for LICs and lower-MICs combined) and interventions delivered in health centres (requiring 49·8% [49·5-50·2] 2015 GNI for LICs and lower-MICs combined) would each comprise the plurality of costs.
Implementation of EUHC would require costly investment, especially in LICs. DCP-CM is available as an online tool that can inform local HBP deliberation and support efficient investment in UHC, especially as countries pivot towards non-communicable disease and injury care.
Bill & Melinda Gates Foundation, Trond Mohn Foundation, and Norwegian Agency for Development Cooperation.
《疾病控制优先事项》第三版(DCP3)公布了两个模式卫生效益套餐(HBPs)。本研究旨在估算这些套餐在低收入国家(LICs)和中低收入国家(lower-MICs)中的总体成本和各个组成部分的成本。
本研究报告了我们的疾病控制优先事项成本模型(DCP-CM),该模型是 DCP3 项目的一部分,用于确定模型 HBP 中推荐的 218 项卫生部门干预措施的总体成本,这些干预措施被称为基本普遍健康覆盖(EUHC)。模型输入包括干预单位成本、人口和流行病学数据,以量化需要特定干预措施的人群、基线覆盖指标以及支持直接服务提供所需的卫生系统成本估算。DCP-CM 主要基于从卫生系统角度衡量干预措施经济成本的已发表估算。我们估计了 2015 年的反事实年度成本。我们根据干预措施的特点(提供平台、提供时间和卫生系统目标)对成本进行了分类,并进行了单向和概率敏感性分析,确定了 95%可信区间(Crls)。
在 80%的人口覆盖率下,EUHC 的年成本在 LICs 中为每人 79 美元(2016 年美元)(95% Crl 60-110),在 lower-MICs 中为每人 130 美元(100-180)。作为 2015 年国民总收入(GNI)的一部分,额外的投资将需要 LICs 中的 8.0%(95% Crl 5.7-11.3)和 lower-MICs 中的 4.2%(2.9-5.9)。由 115 项 EUHC 干预措施组成的最高优先子套餐的成本约为这些金额的一半(LICs 中 2015 年 GNI 的 3.7%[2.6-5.3],lower-MICs 中为 2.0%[1.4-2.8])。降低死亡率的干预措施将占整个套餐成本的三分之二左右,用于降低 5-69 岁非传染性疾病和伤害导致的死亡率的干预措施占这两个收入组 EUHC 总成本的最高份额(LICs 中为 37.6%[37.2-37.9],lower-MICs 中为 43.0%[42.6-43.4])。针对慢性健康状况(LICs 和 lower-MICs 组合需要 2015 年 GNI 的 45.5%[44.8-46.4])和在卫生中心提供的干预措施(LICs 和 lower-MICs 组合需要 2015 年 GNI 的 49.8%[49.5-50.2])的干预措施将各自占成本的多数。
实施 EUHC 将需要昂贵的投资,尤其是在 LICs。DCP-CM 可作为在线工具,为当地 HBP 审议提供信息,并支持全民健康覆盖的有效投资,特别是随着各国转向非传染性疾病和伤害护理。
比尔和梅琳达盖茨基金会、特隆德莫恩基金会和挪威发展合作署。